The American Association for Cancer Research (AACR) has announced the appointment of Timothy A. Yap, MBBS, PhD, as editor-in-chief of Clinical Cancer Research, one of the 10 highly esteemed journals published by the AACR.
Clinical Cancer Research publishes innovative clinical and translational cancer research studies that bridge the laboratory and the clinic, with an emphasis on clinical trials evaluating novel treatments, precision oncology, combination therapy, pharmacology, and molecular alterations or biomarkers that predict response or resistance to treatment.
Yap is the Ransom Horne, Jr. Endowed Professor for Cancer Research in the Department of Investigational Cancer Therapeutics (Phase I Program) at The University of Texas MD Anderson Cancer Center, where he is also vice president and head of clinical development in the Therapeutics Discovery Division and associate director of translational research in the Khalifa Institute for Personalized Cancer Therapy.
An internationally acclaimed leader in clinical and translational cancer research and precision medicine, Yap has served as principal investigator for multiple phase I/II biomarker-driven trials of first-in-class agents and combinations of targeted therapies and immunotherapies, with a focus on DNA repair and synthetic lethality. His main research interests include the targeting of the DNA damage response (DDR) with novel therapeutics, such as inhibitors of PARP1, ATR, WEE1, POLQ, USP1, PKMYT1, PARG, CHK1, ATM, and DNA-PK; next-generation inhibitors of CDK2, CDK4, and CDK7; YAP/TEAD inhibitors; Werner helicase inhibitors; SMARCA2 inhibitors; and the development of novel immunotherapeutics.
Yap’s research has also explored the use of circulating tumor DNA as a predictive biomarker of response and resistance to novel agents in clinical trials. He is also interested in the development of new pharmacodynamic biomarkers and the translational analysis of patient tumors.
Yap has been an active member of the AACR since 2007. He is currently the chair of the AACR Special Conferences Committee; a member of the AACR Clinical Trials Advisory Council; and a member of the AACR Task Force on Precision Combination Therapy.
Click here to read the original press release.
